Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study

SIMPLE SUMMARY: Colorectal cancer (CRC) is the third most frequently diagnosed malignancy worldwide and the second leading cause of cancer-related mortality. In VELOUR phase III trial, aflibercept combined with FOLFIRI has been shown to prolong overall survival versus FOLFIRI plus placebo in metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofheinz, Ralf-Dieter, Anchisi, Sandro, Grünberger, Birgit, Derigs, Hans G., Zahn, Mark-Oliver, Geffriaud-Ricouard, Christine, Gueldner, Max, Windemuth-Kieselbach, Christine, Pederiva, Stefanie, Bohanes, Pierre, Scholten, Felicitas, Piringer, Gudrun, Thaler, Josef, von Moos, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324206/
https://www.ncbi.nlm.nih.gov/pubmed/35884583
http://dx.doi.org/10.3390/cancers14143522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324206/
https://www.ncbi.nlm.nih.gov/pubmed/35884583
http://dx.doi.org/10.3390/cancers14143522

Ejemplares similares